Innovative drug concept stocks stage a short-term rally! CSOP Hang Seng Biotech ETF (03174.HK) surges over 1.5% at the open.

NewTimeSpace News: March 31— Innovative drug concept stocks remained actively traded, with Tianjin Tianyao Pharmaceutical (Jin Yao Pharma) hitting its third consecutive daily limit-up, while Asymchem Laboratories (Kelaiying), JOINN Laboratories (Zhaoyan Xinyao), Pharmaron (Kanglong Huacheng), Haite Bio, and Northgene Pharma (Nuosige) followed suit.CSOP Hang Seng Biotech ETF(03174.HK) surged over 1.5% at the open.

Jin Yao Pharma has locked in daily limit-ups for three straight trading sessions, achieving a "three-board" rally. The company's innovation institute reports that its JYSW003 psoriasis innovative drug project is progressing per contract with favorable early-stage efficacy and safety data. As a major Asian R&D, manufacturing and export base for corticosteroid APIs, the company holds U.S. DMFs for multiple products including prednisone and dexamethasone; export revenue accounts for 32.42% of total sales.

CSOP Hang Seng Biotech ETF(03174.HK), issued by CSOP Asset Management and listed on HKEX, tracks the Hang Seng HK Biotech Index. This index fund focuses on Hong Kong-listed biotech leaders, characterized by high volatility and high beta, suitable for investors bullish on innovative drugs, CXO (CRO/CDMO), vaccines, and gene therapy sectors.

According to media reports, the American Association for Cancer Research (AACR) Annual Meeting will convene in San Diego from April 17-22, where 104 Chinese pharmaceutical companies will present over 250 innovative drug candidates.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.